The makers of Vytorin®, Merck/Schering-Plough Pharmaceuticals, recently issued a controversial press release about the Enhance Study that compared the effects of Vytorin® (a combination of simvastatin and ezetimibe, brand name Zetia®) vs. just simvastatin.
No substantial difference was observed with the addition of Zetia®, perhaps even a negative effect. The news has triggered a media frenzy.
The New York Times headlined the story, "Drug Has No Benefit in Trial." "Drug doesn't slow...
